C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Kato, Mamoru; Sudo, Tomohisa; Tamai, Ikuo; Shiraishi, Yuichi; Okuma, Yusuke; Ogasawara, Daisuke; Suzuki, Tatsuya; Yoshida, Teruhiko; Mano, Hiroyuki

doi:10.1158/2159-8290.cd-22-0417

Cited by 85 publications

(69 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, as pancreaticobiliary cancer has a very poor prognosis, many patients request CGP testing to attempt even the slightest possibility of receiving a new treatment. In the breakdown of CGP testing in Japan, pancreatic and biliary tract cancers were found to be the second and third most frequent cancer types, respectively, after colorectal cancer [ 2 ].…”

Section: Comprehensive Genome Profiling Of Pancreatic Cancersmentioning

confidence: 99%

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile

Hijioka¹,

Nagashio²,

Maruki³

et al. 2023

Diagnostics

View full text Add to dashboard Cite

In recent years, cancer genomic medicine centered on comprehensive genome profile (CGP) analysis has become widely used in the field of pancreatic cancer. Endoscopic ultrasound-guided tissue acquisition (EUS-TA) has played an important role in pancreatic cancer, and recently, more EUS-TA tissue samples are considered for CGP analysis. Differences exist between the Oncoguide NCC Oncopanel System and Foundation One CDx Cancer Genome Profile, which are CGP tests approved by insurance programs in Japan, including the analysis criteria, optimal needle selection for meeting these criteria, and puncture target. It is important to understand not only the specimen collection factors, but also the specimen processing factors that can increase the success rate of CGP testing. Furthermore, cancer genome medicine is expected to enter an era of increasing turbulence in the future, and endoscopists need to respond flexibly to these changes. Herein, we review the current status of cancer genome medicine in pancreatic and biliary tract cancers and cancer gene panel testing using EUS-TA.

show abstract

Section: Comprehensive Genome Profiling Of Pancreatic Cancersmentioning

confidence: 99%

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile

Hijioka¹,

Nagashio²,

Maruki³

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…Characteristics. In June 2019, insurance coverage for the Comprehensive Genome Profiling (CGP) test was introduced in Japan for patients with solid tumours for whom no standard treatment was available or was expected to be completed [33]. The C-CAT was established under the national health insurance system to consolidate, store, and utilise the mutation data and medical information of patients who underwent CGP tests, such as FoundationOne CDx and NCC Oncopanel (https://for-patients.c-cat.ncc.go.jp/).…”

Section: Center For Cancer Genomics and Advanced Therapeutic Cohortmentioning

confidence: 99%

Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer

et al. 2023

Self Cite

View full text Add to dashboard Cite

Background We investigated the utility of a molecular classifier tool and genetic alterations for predicting prognosis in Japanese patients with endometrial cancer. Methods A total of 1029 patients with endometrial cancer from two independent cohorts were classified into four molecular subtype groups. The primary and secondary endpoints were relapse-free survival (RFS) and overall survival (OS), respectively. Results Among the 265 patients who underwent initial surgery, classified according to immunohistochemistry, patients with DNA polymerase epsilon exonuclease domain mutation had an excellent prognosis (RFS and OS), patients with no specific molecular profile (NSMP) and mismatch repair protein deficiency had an intermediate prognosis, and those with protein 53 abnormal expression (p53abn) had the worst prognosis (P < 0.001). In the NSMP group, mutant KRAS and wild-type ARID1A were associated with significantly poorer 5-year RFS (41.2%) than other genomic characteristics (P < 0.001). The distribution of the subtypes differed significantly between patients with recurrence/progression and classified by sequencing (n = 764) and patients who underwent initial surgery (P < 0.001). Among patients with recurrence/progression, 51.4% had the opportunity to receive molecular targeted therapy. Conclusions A molecular classifier is a useful tool for determining prognosis and eligibility for molecularly targeted therapy in patients with endometrial cancer.

show abstract

“…Furthermore, some patients who had completed the standard treatment could not enroll in the clinical trial of new drugs matched by CGP because of their deteriorated physical condition and restriction of the acceptable treatment line. [9][10][11][12] In addition, CGP for patients who had completed the SOC did not achieve an improved prognosis. 13,14 The National Comprehensive Cancer Network and the European Society for Medical Oncology recommend the use of CGP for selected cancers in daily practice, 5,7 as well as for research purposes in academic centers.…”

Section: Introductionmentioning

confidence: 96%

“…Given the indication in Japan, many patients may miss an opportunity to receive molecularly matched therapies early in their treatment. Furthermore, some patients who had completed the standard treatment could not enroll in the clinical trial of new drugs matched by CGP because of their deteriorated physical condition and restriction of the acceptable treatment line . In addition, CGP for patients who had completed the SOC did not achieve an improved prognosis .…”

Section: Introductionmentioning

confidence: 99%

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities

et al. 2023

View full text Add to dashboard Cite

IMPORTANCEPrecision oncology using comprehensive genomic profiling (CGP) by next-generation sequencing is aimed at companion diagnosis and genomic profiling. The clinical utility of CGP before the standard of care (SOC) is still not resolved, and more evidence is needed.OBJECTIVETo investigate the clinical utility of next-generation CGP (FoundationOne CDx [F1CDx]) in patients with previously untreated metastatic or recurrent solid tumors.DESIGN, Setting, and ParticipantsThis multicenter, prospective, observational cohort study enrolled patients with previously untreated advanced solid tumors between May 18, 2021, and February 16, 2022, with follow-up through August 16, 2022. The study was conducted at 6 hospitals in Japan. Eligible patients were aged 20 years or older and had Eastern Cooperative Oncology Group performance status of 0 to 1 with previously untreated metastatic or recurrent cancers in the gastrointestinal or biliary tract; pancreas, lung, breast, uterus, or ovary; and malignant melanoma.EXPOSUREComprehensive genomic profiling testing before SOC for advanced solid tumors.MAIN OUTCOMES AND MEASURESProportion of patients with actionable or druggable genomic alterations and molecular-based recommended therapy (MBRT).RESULTSA total of 183 patients met the inclusion criteria and 180 patients (92 men [51.1%]) with a median age of 64 years (range, 23-88 years) subsequently underwent CGP (lung [n = 28], colon/small intestine [n = 27], pancreas [n = 27], breast [n = 25], biliary tract [n = 20], gastric [n = 19], uterus [n = 12], esophagus [n = 10], ovary [n = 6], and skin melanoma [n = 6]). Data from 172 patients were available for end point analyses. Actionable alterations were found in 172 patients (100.0%; 95% CI, 97.9%-100.0%) and druggable alternations were identified in 109 patients (63.4%; 95% CI, 55.7%-70.6%). The molecular tumor board identified MBRT for 105 patients (61.0%; 95% CI, 53.3%-68.4%). Genomic alterations included in the companion diagnostics list of the CGP test were found in 49 patients (28.5%; 95% CI, 21.9%-35.9%) in a tumor-agnostic setting. After a median follow-up of 7.9 months (range, 0.5-13.2 months), 34 patients (19.8%; 95% CI, 14.1%-26.5%) received MBRT.CONCLUSIONS AND RELEVANCEThe findings of this study suggest that CGP testing before SOC for patients with advanced solid tumors may be clinically beneficial to guide the subsequent anticancer therapies, including molecularly matched treatments.

show abstract

C-CAT: The National Datacenter for Cancer Genomic Medicine in Japan

Cited by 85 publications

References 25 publications

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile

Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreaticobiliary Cancer Aiming for a Comprehensive Genome Profile

Utility of molecular subtypes and genetic alterations for evaluating clinical outcomes in 1029 patients with endometrial cancer

First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities

Contact Info

Product

Resources

About